MARKET

INCY

INCY

Incyte Corp
NASDAQ
101.42
+2.65
+2.68%
After Hours: 101.99 +0.57 +0.56% 19:43 01/02 EST
OPEN
98.25
PREV CLOSE
98.77
HIGH
101.50
LOW
97.94
VOLUME
2.15M
TURNOVER
--
52 WEEK HIGH
109.28
52 WEEK LOW
53.56
MARKET CAP
19.91B
P/E (TTM)
17.15
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INCY last week (1222-1226)?
Weekly Report · 12/29/2025 10:16
Incyte (INCY) Receives a Hold from Truist Financial
TipRanks · 12/24/2025 12:15
Incyte price target raised to $103 from $93 at Truist
TipRanks · 12/24/2025 12:10
U.S. RESEARCH ROUNDUP-Incyte, ServiceNow, Spire Global
Reuters · 12/24/2025 11:30
INCYTE <INCY.O>: TRUIST SECURITIES RAISES TARGET PRICE TO $103 FROM $93
Reuters · 12/24/2025 03:34
Incyte (INCY) Valuation Check After Japan Oncology Approvals for Minjuvi and Zynyz
Simply Wall St · 12/23/2025 08:18
Incyte Secures Dual Approvals In Japan For Zynyz And Minjuvi
NASDAQ · 12/22/2025 15:01
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?
NASDAQ · 12/22/2025 14:03
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.